RESUMEN
The ascomycete Dichotomomyces cejpii was isolated from the marine sponge Callyspongia cf. C. flammea. Three new steroids (1-3), two of which are present as glycosides, with an untypical pattern of carbon-carbon double bounds, were obtained from fungal extracts, as well as the known xanthocillin X dimethyl ether (4). Compounds 2 and 4 were evaluated in an Alzheimer's disease cellular assay and found capable of preventing the enhanced production of amyloid ß-42 in Aftin-5 treated cells. Aß-42 lowering agents are considered as candidates for the treatment of neurodegenerative Alzheimer's disease.
Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Péptidos beta-Amiloides/biosíntesis , Ascomicetos/química , Butadienos/farmacología , Fragmentos de Péptidos/biosíntesis , Poríferos/microbiología , Esteroles/aislamiento & purificación , Esteroles/farmacología , Enfermedad de Alzheimer/metabolismo , Animales , Butadienos/química , Butadienos/aislamiento & purificación , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Humanos , Estructura Molecular , Esteroles/química , Relación Estructura-ActividadRESUMEN
The Ascomycota Dichotomomyces cejpii was isolated from the marine sponge Callyspongia cf. C. flammea. A new gliotoxin derivative, 6-acetylmonodethiogliotoxin (1) was obtained from fungal extracts. Compounds 2 and 3, methylthio-gliotoxin derivatives were formerly only known as semi-synthetic compounds and are here described as natural products. Additionally the polyketide heveadride (4) was isolated. Compounds 1, 2 and 4 dose-dependently down-regulated TNFα-induced NF-κB activity in human chronic myeloid leukemia cells with IC50s of 38.5 ± 1.2 µM, 65.7 ± 2.0 µM and 82.7 ± 11.3 µM, respectively. The molecular mechanism was studied with the most potent compound 1 and results indicate downstream inhibitory effects targeting binding of NF-κB to DNA. Compound 1 thus demonstrates potential of epimonothiodiketopiperazine-derived compounds for the development of NF-κB inhibitors.